Several tests for PCR-based detection and molecular characterization of circulating tumor cells (CTC) are under development.
The list of future products comprises multi-marker tests for breast cancer, lung cancer, ovarian cancer, cervical cancer, endometrial cancer, and neuroendocrine tumors. Tools and reagents for collecting and stabilizing patients‘ blood samples, enrichment of circulating rare cells (CRC), or depletion of unwanted cells are in the pipeline as well.
Methods and tests for the detection and quantification of protein aggregates are another focus of research and product development at OncoLab. Inactivation of protein function by aggregation plays an important role in cancer and several other diseases, like neurodegenerative disorders, amyloid transthyretin cardiomyopathy and type-2 diabetes. Products for the detection and quantification of disease associated aggregated proteins in tissues, cells and microvesicles are under development.
The diagnostic impact of cell-free circulating RNA (cfRNA) levels in various bodily fluids and preparation of exosomes is another research topic.
Proprietary mRNAs and miRNAs are investigated as possible diagnostic targets for gynecologic malignancies and other cancerous diseases.